MannKind Drops After Hours After FDA Will Not Likely Accept Ongoing Trials (MNKD)

MannKind MNKD falls today in after-hours trading as FDA tells the company it will not likely accept ongoing trials of MannKind's AFREZZA. “We recently held a productive End-of-Review meeting with the FDA regarding the path forward for AFREZZA,” said Alfred Mann, Chairman and Chief Executive Officer of MannKind Corporation. “In this meeting, we were able to clarify many details about the FDA's requirements for approval of AFREZZA, and the agency indicated that its minutes of the meeting would contain additional advice regarding aspects of our planned studies. Once the protocols are finalized, we are ready to initiate the required clinical studies at sites in the United States, Europe and Latin America. As always, we remain committed to our goal of providing a novel treatment to the millions of patients with diabetes.”